The current lead programs of Therasid Bioscience are NASH and AD which are global hot spot due to its deficiencies of approved or efficacious treatment.
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. During the past 20 years the incidence of NAFLD has more than doubled. NASH is severe form of NAFLD but there is no approved therapy for NASH. Therasid Bioscience is challenging on creating intervention for NASH, covering every stage of disease progresses from the early stage metabolic disorder to liver fibrosis.
On the basis of our experiences and platform technology, neurodegenerative disease, especially in Alzheimer’s disease, became a second lead program of our company. We believe that amyloid hypothesis is still effective and there must be more creative and multi-modal approaches for success of making treatment of Alzheimer’s disease.